CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 126 enrolled
Drug / intervention
"Probiotics" and "Metronidazole" +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03894813
NCT03894813Phase 4Completed
CompareCT.gov

Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital

Peking University Shenzhen Hospital·interventional·Posted Mar 29, 2019·Updated Jul 9, 2021

In Brief

A Phase 4 clinical trial evaluating "Probiotics" and "Metronidazole" and Metronidazole Vaginal for Bacterial Vaginosis. Completed, enrolled 126 participants across 1 site.

Detailed Summary

The investigators are trying to determine if oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (30 days)with metronidazole vaginal suppositories(7 days) is better than using metronidazole vaginal suppositories only in preventing the recurrence of bacterial vaginosis (BV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis
CountriesChina
CollaboratorsBGI, China

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMar 29, 2019
Enrollment StartMar 26, 2019
Primary CompletionDec 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.3 years ago

Interventions

"Probiotics" and "Metronidazole"drug

Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)

Metronidazole Vaginaldrug

Metronidazole Suppositories,qd, 7 days